Long-term outcome of allogeneic or autologous haemopoietic cell transplantation for acute lymphoblastic leukaemia in second remission in children. GETMON experience 1983-1998

Bone Marrow Transplantation

Volumn 35, Issue 9, 2005, Pages 895-901

  Badell, I ^a   Munoz A ^b   Ortega, J J ^c   Martinez A ^d   Madero, L ^e   Bureo, E ^f   Verdeguer, A ^g   Fernandez Delgado, R ^h   Cubells, J ^a   Soledad Maldonado, M ^b   Olive T ^c   Sastre, A ^d   Baro, J ^e   Diaz M A ^e  

^a HOSPITAL SANT PAU   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Acute lymphoblastic leukaemia; Children; Haemopoietic cell transplantation

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 20844458253     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704932     Document Type: Article

References (47)

1. Rubnitz JE, Pui CH. Recent advances in the treatment and understanding of childhood acute lymphoblastic leukaemia. Cancer Treat Rev 2003; 29: 31-44.
2. Miniero R, Saracco P, Pastore G et al. Relapse after cessation of therapy in childhood acute lymphoblastic leukaemia: a 10-year follow-up study. Italian Association of Paediatric Hematology-Oncology (AEIOP). Med Pediatr Oncol 1995; 24: 71-76.
3. Pui CH, Evans WE. Acute lymphoblastic leukaemia. N Engl J Med 1998; 339: 605-615.
4. Uderzo C, Conter V, Dini G et al. Treatment of childhood acute lymphoblastic leukaemia after the first relapse: curative strategies. Haematologica 2001; 86: 1-7.
5. Adams HP, Henze G. Treatment of children with relapsed acute lymphoblastic leukaemia. Studies of the BFM Study Group. In: Hiddemann W, Adams HP, Henze G (eds). Acute Leukaemias VII. Springer-Verlag: Berlin, 1998, pp 735-740.
6. Lawson SE, Harrison G, Richards S et al. The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol 2000; 108: 531-534.
7. Buchanan GR, Rivera GK, Pollock BH et al. Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukaemia in second bone marrow remission: a Paediatric Oncology Group Study. Cancer 2000; 88: 1166-1174.
8. Dopfer R, Henze G, Bender-Gotze C et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission after intensive primary and relapse therapy according to the BFM-and CoALL-protocols: results of the German Cooperative Study. Blood 1991; 78: 2780-2784.
9. Barrett AJ, Horowitz MM, Pollock BH et al. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukaemia in a second remission. N Engl J Med 1994; 331: 1253-1258.
10. Weisdorf DJ, Woods WG, Nesbit ME et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia. Risk factors and clinical outcome. Br J Haematol 1994; 86: 62-69.
11. Moussalem M, Esperou Bourdeau H, Devergie A et al. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission. Factors predictive of survival, relapse and graft-versus-host disease. Bone Marrow Transplant 1995; 15: 943-947.
12. Torres A, Alvarez MA, Sanchez J et al. Allogeneic bone marrow transplantation vs chemotherapy for the treatment of childhood acute lymphoblastic leukaemia in second complete remission (revisited 10 years on). Bone Marrow Transplant 1999; 23: 1257-1260.
13. Bordignoni P, Esperou H, Souillet G et al. Total body irradiation-high-dose cytosine arabinoside and melphalan followed by allogeneic bone marrow transplantation from HLA-identical siblings in the treatment of children with acute lymphoblastic leukaemia after relapse while receiving chemotherapy: a Société Française de Greffe de Moelle study. Br J Haematol 1998; 102: 656-665.
14. Uderzo C, Valsecchi MG, Bacigalupo A et al. Treatment of childhood acute lymphoblastic leukaemia in second remission with bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Paediatric Hematology Oncology Association. J Clin Oncol 1995; 134: 352-358.
15. Belasco JB, Goldwein JW, Simms S et al. Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukaemia in children. Med Pediatr Oncol 2000; 32: 123-131.
16. Ramsay N, LeBien T, Weisdorf D et al. Autologous BMT for patients with acute lymphoblastic leukaemia. In: Gale R, Champlin R (eds). Bone Marrow Transplantation: Current controversies. Alan R Liss: New York, 1989, pp 57-66.
17. Schroeder H, Pinkerton CR, Powles RJ et al. High dose melphalan and total body irradiation with autologous marrow rescue in childhood acute lymphoblastic leukaemia after relapse. Bone Marrow Transplant 1991; 1: 7-15.
18. Billett AL, Kornmehl E, Tarbell NJ. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukaemia. Blood 1993; 81: 1651-1657.
19. Doney K, Buckner CD, Fisher L et al. Autologous bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant 1993; 12: 315-321.
20. Maldonado MS, Diaz-Heredia C, Badell I et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukaemia in second remission. Spanish Working Party for BMT in Children. Bone Marrow Transplant 1998; 22: 1043-1047.
21. Vaidya SJ, Atra A, Bahl S et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission-long-term follow-up. Bone Marrow Transplant 2000; 25: 599-603.
22. Balduzzi A, Gaipa G, Bonanoni S et al. Purified autologous grafting in childhood acute lymphoblastic leukaemia in second remission: evidence for long-term clinical and molecular remissions. Leukaemia 2001; 15: 50-56.
23. Parsons SK, Castellino SM, Lehmann LE et al. Relapsed acute lymphoblastic leukaemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children. Bone Marrow Transplant 1996; 17: 763-768.
24. Uderzo C, Rondelli R, Dini G et al. High-dose vincristine, fractionate total-body irradiation and cyclophosphamide as conditioning regimen in allogeneic and autologous bone marrow transplantation for childhood acute lymphoblastic leukaemia in second remission: a 7-year Italian multicentre study. Br J Haematol 1995; 89: 790-797.
25. Bezanilla JL, Cubells J, Muñoz A et al. Treatment of acute lymphoblastic leukaemia with the SHOP-89 Protocol. Preliminary results. Med Pediatr Oncol 1992; 20: 407.
26. Ortega JJ, Ribera JM, Oriol A et al. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukaemia. Final results of the prospective randomised PETHEMA ALL-89 Trial. Haematologica 2001; 86: 586-595.
27. Badell I, Ortega JJ, Muñoz A et al. Trasplante alogénico de médula ósea versus autotrasplante en la leucemia aguda linfoblástica en segunda remision en 113 niños. Sangre 1996; 41: 101-108.
28. Dai Q, Souillet G, Bertrand Y et al. Antileukemic and long-term effects of two regimens with or without TBI in allogeneic bone marrow transplantation for chilhood acute lymphoblastic leukemia. Bone Marrow Transplant 2004; 34: 667-673.
29. Shalet SM, Didi M, Ogilvy-Stuart AL et al. Growth and endocrine function after bone marrow transplantation. Clin Endocrinol 1995; 42: 333-339.
30. Kersey JH, Weisdorf D, Nesbit ME et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high risk refractory acute lymphoblastic leukaemia. N Engl J Med 1987; 317: 461-467.
31. Blaire D, Gaspard MH, Stoppa AM et al. Allogeneic and autologous bone marrow transplantation for acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 1990; 5: 7-12.
32. Bacigalupo A, Sormani MP, Lamparelli T et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 2004; 89: 238-249.
33. Carreras E, Bertz M, Arcese W et al. Incidence and outcome of hepatic veno-occlusive disease after blood and marrow transplantation of the European Group for Blood and Marrow transplantation. Blood 1998; 92: 3599-3604.
34. Vicent MG, Madero L, Ortega JJ et al. Matched-pair analysis comparing allogeneic PBPCT and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia. Bone Marrow Transplant 2002; 30: 9-13.
35. Sufhianska S, Horakova J, Bodova I et al. Allogeneic peripheral stem-cell transplantations in children. A single center experience. Neoplasia 2004; 51: 110-116.
36. Diaz MA, Vicent MG, Gonzalez ME et al. Risk assessment and outcome of chronic graft versus host disease after allogeneic peripheral blood progenitor cells transplantation in paediatric patients. Bone Marrow Transplant 2004; 34: 433-438.
37. Saarinen-Pihkala UM, Gustafsson G, Ringden O et al. No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001; 19: 3406-3414.
38. Al-Kassim FA, Thornley I, Rolland M et al. Single-centre experience with allogeneic bone marrow transplantation for acute lymphoblastic leukemia in children: similar survival after matched-related and matched-unrelated donor transplants. Br J Haematol 2002; 11: 483-490.
39. Weisdorf D, Bishop M, Dharan B et al. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant 2002; 8: 213-220.
40. Rosseti R, Messina C, Miniero R et al. Autologous bone marrow transplantation for early extramedullary relapse of childhood acute lymphoblastic leukaemia. Bone Marrow Transplant 1993; 12: 33-41.
41. Colleselli P, Rosseti F, Messina C et al. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in remission: first choice for isolated extramedullary relapse? Bone Marrow Transplant 1994; 14: 821-825.
42. Weisdorf D, Billet AL, Hannan P et al. Autologous versus unrelated donor allogeneic marrow transplantation in acute lymphoblastic leukaemia. Blood 1997; 90: 2962-2968.
43. Borgmann A, Schmid H, Hartmann R et al. Autologous bone marrow transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in second remission: a matched-pair analysis. The BFM study Group. Lancet 1995; 346: 873-876.
44. Chessells JM, Veys P, Kemski H et al. Long-term follow-up of relapsed acute lymphoblastic leukemia. Br J Haematol 2003; 123: 396-405.
45. Badell I, Olivé T, Muñoz A et al. Secondary malignancies after hematopoietic cell transplantation in children. Bone Marrow Transplant 2003; 31 (Suppl. 1): S110 (abstract P 500).
46. Loning L, Zimmermann M, Reiter A et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000; 95: 2770-2775.
47. Bathia S, Sather HN, Pabustan OB et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002; 99: 4242-4257.